Pyridorin pyridoxamine: Phase IIb data

The double-blind, U.S. Phase IIb PYR-210 trial in 307 evaluable patients showed that twice-daily 150 and 300 mg Pyridorin each missed the primary endpoint of significantly reducing the progressive increase in serum

Read the full 320 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE